Autophagy in Alzheimer’s Disease: Mechanisms, Clinical Trials, and Horizons
Neurodegenerative Diseases · 09.07.2026 · 1-16
DOI: 10.1159/000553506 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Neurodegenerative Diseases, online erschienen am 09.07.2026. Verfasst von Tshibambe N Tshimbombu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS.
Themen: Demenz
Abstract (Originalsprache)
Background: Alzheimer’s disease (AD) is an incurable progressive neurodegenerative disorder characterized by the pathological accumulation of amyloid beta (Aβ) plaques and neurofibrillary tangles in the brain. Recent findings have identified dysregulation of autophagy, a cellular mechanism for degradation and recycling, as a crucial contributor to the pathogenesis of AD. This narrative review examines the role of autophagy in the metabolism of Aβ and tau and evaluates current therapeutic strategies aimed at modulating autophagic pathways. Summary: Autophagy is governed by the key molecular regulators mammalian target of rapamycin, adenosine monophosphate-activated protein kinase, Beclin-1, and transcription factor EB, which collectively control the clearance of protein recycling, including aggregates, inside cells. Pharmacological agents such as rapamycin, resveratrol, and trehalose, alongside sigma-1 receptor agonists and gene therapy approaches, have demonstrated potential in modulating autophagy in preclinical and clinical studies. Despite these advances, significant challenges persist, namely, neuronal heterogeneity, optimal timing for therapeutic intervention, and the absence of reliable biomarkers to monitor autophagic activity and treatment efficacy. Key Messages: Targeting autophagy offers a promising and potentially safe avenue for slowing AD progression. Future investigations should prioritize the development of selective autophagy modulators and personalized treatment strategies to restore autophagic flux and enhance clinical outcomes in patients with AD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA.
- School of Medicine, Creighton University, Phoenix, Arizona, USA.
- Department of Pharmacology and Neuroscience, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas, USA.
- Center for Tropical Diseases and Global Health, Faculty of Medicine, Université Catholique de Bukavu, Bukavu, Congo.
- School of Medicine, University of Ghana, Accra, Ghana.
- Faculty of Medicine, Université Catholique de Bukavu, Bukavu, Congo.
Förderung
- NIA NIH HHS
Zitieren
APA
Tshimbombu, T. N., Thurmann, K. E., Decourt, B., Nyalundja, A. D., Shardow, S. B., Amoako, M. E., Iragi, G. M., Mwambali, J. A., & Sabbagh, M. N. (2026). Autophagy in Alzheimer’s Disease: Mechanisms, Clinical Trials, and Horizons. Neurodegenerative Diseases, 1-16. https://doi.org/10.1159/000553506
Vancouver
Tshimbombu TN, Thurmann KE, Decourt B, Nyalundja AD, Shardow SB, Amoako ME, et al. Autophagy in Alzheimer’s Disease: Mechanisms, Clinical Trials, and Horizons. Neurodegenerative Diseases. 2026:1-16. doi:10.1159/000553506
BibTeX
@article{Tshimbombu2026,
author = {Tshimbombu, Tshibambe N and Thurmann, Kyle E and Decourt, Boris and Nyalundja, Arsene Daniel and Shardow, Samira Braimah and Amoako, Melissa Ewurakua and Iragi, Gates Mulume and Mwambali, Josué Aganze and Sabbagh, Marwan N},
title = {Autophagy in Alzheimer’s Disease: Mechanisms, Clinical Trials, and Horizons},
journal = {Neurodegenerative Diseases},
year = {2026},
pages = {1--16},
doi = {10.1159/000553506}
}
EUVIMED